FDA Peptide Compounding Status Tracker (2026): Where BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax And DSIP Actually Stand

At-a-Glance Comparison

Nominated uses are quoted from FDA's April 16, 2026 Federal Register meeting notice (Docket FDA-2025-N-6895). No final rule or current 503A-list authorization was identified for any substance listed as of September 17, 2026. An advisory discussion or recommendation is not authorization.

What The Advisory Process Could Decide

The Pharmacy Compounding Advisory Committee advises the FDA on whether a bulk drug substance belongs on the Section 503A Bulk Drug Substances List. It does not approve drugs or set policy. Eligibility still depends on the applicable 503A or 503B pathway, FDA policy, and state law.

Read the mechanism, because it determines what an advisory process can change. The FDA evaluates nominated substances against a four-part standard covering physicochemical characterization, safety, effectiveness, and historical use in compounding. The April 16 meeting notice sets the review scope, but it does not create current compounding authority. That is why the next step is policy review rather than immediate effect. Track the docket at Docket No. FDA-2025-N-6895 rather than relying on headlines that turn an advisory discussion into clearance.

Common failure mode: a non-binding advisory process gets sold as regulatory approval, and buyers conclude that a legal supply now exists when it does not.

Why An Advisory Discussion Does Not Mean 'Available'

Between an advisory discussion and a legally compoundable substance sits a formal rulemaking process with a proposed rule, a public comment window, and a final determination.

The practical consequence is a process whose timing and outcome are not guaranteed to match an advisory discussion. No final rule or current 503A-list authorization for these substances was identified in the September 17 check, and the advisory process does not itself establish compounding authority. Eligibility depends on the applicable 503A or 503B pathway, FDA policy, and state law; pharmaceutical-grade ingredient availability is a separate question. Anyone selling you BPC-157 on the strength of an advisory discussion is presenting a non-binding process as permission. Recheck the docket and ask a licensed clinician or pharmacist about current status.

Common failure mode: sellers use an advisory discussion as a marketing event, and a 'research chemical' purchase gets reframed as an anticipatory-but-legitimate one.

The Nominated Use Is Narrower Than The Marketed Use

Each substance was nominated for a specific clinical indication, and for several of these peptides that indication has little overlap with how the compound is actually sold.

Compare the table's second column against the marketing you have encountered. BPC-157 is nominated for ulcerative colitis, while it is overwhelmingly marketed for tendon, joint and soft-tissue recovery. Epitalon is nominated for insomnia and marketed for longevity and telomere effects. MOTS-c is nominated for obesity and osteoporosis and marketed for mitochondrial performance. This gap matters twice: it tells you what evidence the FDA was actually asked to weigh, and it means that even a favorable final rule would not validate the performance and longevity claims that drive most consumer demand. Read the BPC-157 guide and the peptide prescription guide alongside this page.

Common failure mode: a favorable ruling on a narrow indication is generalized into blanket validation of every claim made about the compound.

What Happens Next And When To Recheck

A second advisory committee panel is expected to review an additional set of peptides, and any rulemaking on the July substances would proceed on its own schedule.

Set a recheck cadence rather than watching the news cycle. The two things that would represent genuine change are a proposed rule appearing in the Federal Register under Docket FDA-2025-N-6895, and a subsequent final rule. Searching the Federal Register for the substance name directly is faster and more reliable than following trade coverage, and it costs nothing. We re-verify this page's status column on a monthly cadence and on any docket movement. If you are making a decision that depends on legal status, check the docket the same week you decide — this page states its verification date for exactly that reason.

Common failure mode: a status page is read months after publication and treated as current when the underlying docket has moved.

What This Means If You Are Currently Sourcing Peptides

The regulatory question and the safety question are related but distinct, and the July advisory process resolved neither.

If you are buying peptides labeled 'not for human use' from research suppliers, the July advisory process changed nothing about that transaction's legal or safety profile. Product identity, purity, sterility and dosing accuracy remain unverified in that channel regardless of what an advisory body discussed. If you are working with a clinician, the productive conversation is about which FDA-approved options address your actual goal, what monitoring you need, and what the clinician will and will not prescribe. Bring the distinction between recommendation and rule into that conversation — a provider who tells you these peptides are now cleared is telling you something verifiably untrue, and that is useful information about the provider.

Common failure mode: regulatory optimism substitutes for supply-chain diligence, and an unverified product is treated as safer than it was last month.

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

Regulatory status changes slowly and headlines change fast. Before you spend money on the strength of a news cycle, verify the docket — and if you are building an actual protocol, build it around what is approved and monitored today.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

Did the FDA approve BPC-157 for compounding in July 2026?

No. The July 2026 advisory process was non-binding and did not itself establish pharmacy authority. No final rule or current 503A-list authorization for BPC-157 was identified as of the September 17, 2026 Federal Register check; eligibility depends on the applicable 503A or 503B pathway, FDA policy, and state law.

What substances did the FDA meeting notice identify for review?

The April 16, 2026 FDA meeting notice identifies seven nominated substances: BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and emideltide (DSIP). It also identifies the proposed review topics. A meeting notice and any later advisory discussion do not establish current compounding authority.

Can a compounding pharmacy legally make BPC-157 for me right now?

The September 17, 2026 check identified no final rule or current 503A-list authorization for these substances. An advisory discussion does not itself establish authority. Whether a product may be prepared depends on the applicable 503A or 503B pathway, FDA policy, and state law; ingredient availability and compounding eligibility are separate questions.

What were these peptides actually nominated to treat?

Per FDA's April 16, 2026 meeting notice: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, Semax for cerebral ischemia and migraine, Epitalon for insomnia, and emideltide for opioid withdrawal and chronic pain indications. Several of these differ substantially from how the compounds are marketed to consumers.

Did FDA scientists support adding these peptides to the list?

The April 16 FDA meeting notice describes the nominated substances and review scope; it is not an authorization or efficacy finding. Any later eligibility decision remains subject to the applicable 503A or 503B pathway, FDA policy, and state law.

How do I check whether the status has changed since this page was written?

Search the Federal Register for the substance name or for Docket No. FDA-2025-N-6895. The first meaningful change would be publication of a proposed rule, followed later by a final rule. This is faster and more reliable than following trade press, which has reported this story inconsistently. This page's status column was verified on September 17, 2026.